Immunic, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a IMUX research report →
Companywww.immunic-therapeutics.com
Immunic, Inc. , a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease.
- CEO
- Daniel Vitt
- IPO
- 2014
- Employees
- 91
- HQ
- New York City, NY, US
Price Chart
Valuation
- Market Cap
- $113.98M
- P/E
- -3.34
- P/S
- 0.00
- P/B
- 2.30
- EV/EBITDA
- 0.66
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -220.75%
- ROIC
- -72.29%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-97,172,000 · 3.32%
- EPS
- $-6.24 · 37.60%
- Op Income
- $-103,228,000
- FCF YoY
- -1.10%
Performance & Tape
- 52W High
- $15.10
- 52W Low
- $5.06
- 50D MA
- $11.36
- 200D MA
- $8.74
- Beta
- 1.21
- Avg Volume
- 296.33K
Get TickerSpark's AI analysis on IMUX
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 16, 26 | BONNEY MICHAEL W | other | 0 |
| Apr 24, 26 | Panzara Michael A. | other | 300,000 |
| Apr 24, 26 | Panzara Michael A. | other | 0 |
| Mar 27, 26 | Congleton Jon | other | 0 |
| Feb 17, 26 | BVF PARTNERS L P/IL | other | 0 |
| Feb 17, 26 | BVF PARTNERS L P/IL | other | 0 |
| Feb 17, 26 | BVF PARTNERS L P/IL | other | 0 |
| Feb 17, 26 | BVF PARTNERS L P/IL | other | 3,202,262 |
| Feb 17, 26 | BVF PARTNERS L P/IL | other | 3,202,262 |
| Feb 17, 26 | Nagel Robert Thorvald | other | 0 |
Our IMUX Coverage
We haven't published any research on IMUX yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate IMUX Report →